Very recently, FDA approval was granted for Idecabtagene Vicleucel (Abecma developed by Celgene Corporation, New Jersey, NJ, USA), the first cell-based therapy (an anti-BCMA CAR with 4-1BB costimulatory domain) to treat adult patients with multiple myeloma. This evidence concerns the gene TNFRSF17 and AL amyloidosis.